AC Immune (NASDAQ:ACIU) Rating Lowered to Hold at StockNews.com

AC Immune (NASDAQ:ACIU) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Monday.

Separately, HC Wainwright cut their price target on AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 1st.

AC Immune Trading Down 5.0 %

Shares of ACIU opened at $1.63 on Monday. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.98. The stock has a market capitalization of $163.17 million, a P/E ratio of -3.53 and a beta of 1.62. The business’s 50-day moving average price is $1.88 and its 200 day moving average price is $2.54.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $1.12 million for the quarter, compared to analysts’ expectations of $1.99 million. On average, research analysts predict that AC Immune will post -0.62 earnings per share for the current year.

Institutional Trading of AC Immune

A number of hedge funds have recently modified their holdings of ACIU. Geode Capital Management LLC lifted its position in AC Immune by 6.4% in the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock worth $220,000 after purchasing an additional 3,499 shares during the period. RPO LLC acquired a new position in shares of AC Immune in the 4th quarter valued at $51,000. Renaissance Technologies LLC raised its stake in shares of AC Immune by 14.6% in the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock valued at $1,999,000 after buying an additional 94,191 shares in the last quarter. Quinn Opportunity Partners LLC bought a new position in shares of AC Immune during the 4th quarter worth about $27,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of AC Immune by 130.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after acquiring an additional 74,358 shares in the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.